Transjugular Intrahepatic Portosystemic Shunt With or Without Branched-Chain Amino Acid Supplements in the Treatment of Patients With Cirrhotic Portal Hypertension Complicated by Sarcopenia: A Randomized Controlled Trial

What this Trial Is About

Cirrhosis is a serious global health issue causing significant illness and death among patients with chronic liver disease. It often leads to portal hypertension and life-threatening complications such as ascites, variceal bleeding, and hepatic encephalopathy. Transjugular intrahepatic portosystemic shunt (TIPS) is a recommended treatment for variceal bleeding and refractory ascites according to major liver disease guidelines. Malnutrition and sarcopenia (severe muscle loss) are common in cirrhosis and worsen patient outcomes, especially after TIPS treatment. This study aims to evaluate the effects of branched-chain amino acid (BCAA) supplements on muscle mass and clinical outcomes in cirrhotic patients undergoing TIPS. Participants are randomly assigned to one of two groups: the experimental group receives oral BCAA supplements for three months starting after the TIPS procedure, while the control group receives a placebo that looks and tastes the same for the same duration. TIPS is performed using standard techniques with covered stents and may include variceal embolization if needed. The study follows patients for one year to compare muscle improvement and clinical events between groups. During the study, participants undergo assessments including muscle mass measurements and physical performance tests. Researchers also track complications like hepatic encephalopathy, rebleeding, shunt dysfunction, and survival over one year. The study collects data on sarcopenia reversal rates and physical performance scores as primary outcomes. Safety and clinical progress are monitored throughout, with the total participation lasting one year after treatment.

TIPS With or Without BCAA